Trial Search Results
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
Stanford is currently accepting patients for this trial.
- Drug: 68Ga-DOTA TATE
- Greater than 18 years-old at the time of radiotracer administration
- Provides written informed consent
- Known diagnosis of NET or suspected SSTR positive tumors by 111In-Octreotide scan,
18FDG-PET, or MRI of the abdomen when clinically indicated
- Karnofsky score greater than 50 or ECOG Performance Status 0-2
- Women of childbearing age must have a negative pregnancy test at screening/baseline
- Able to remain still for duration of each imaging procedure (about one hour)
- Less than 18 years-old at the time of radiotracer administration
- Pregnant or nursing
- Serum creatinine >3.0 mg/dL
- Hepatic enzyme levels more than 5 times upper limit of normal.
- Use of any other investigational product or device within 30 days prior to dosing, or
known requirement for any other investigational agent prior to completion of all
scheduled study assessments.
- Inability to lie still for the entire imaging time
- Inability to complete the needed investigational and standard-of-care imaging
examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
- Any additional medical condition, serious intercurrent illness, or other extenuating
circumstance that, in the opinion of the Investigator, may significantly interfere
with study compliance.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study